Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Sen. Bill Cassidy’s report calls on Congress to improve the transparency of the drug discount program in a move praised by ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...